CAJ | 학술논문

目的：评价胎儿纤维连接蛋白(fFN)和胰岛素样生长因子结合蛋白-1(IGFBP-1)在早产预测中的临床价值。方法选择先兆早产孕妇210例，随机分为三组各70例，应用免疫法定性检测宫颈阴道分泌物中的fFN和IGFBP-1。A组行fFN检测，B组行IGFBP-1检测，C组行二者联合检测，观察7d、14d内分娩结局，计算三种方法预测早产的灵敏度、特异性、阳性预测值、阴性预测值和诊断符合率。结果 A组中19例阳性,51例阴性。B组中21例阳性，49例阴性。C组两者之一阳性或两者均阳性或共33例，两者均阴性37例。三种检测方法在7d和14d内预测的灵敏度、特异度、阳性预测值、阴性预测值和诊断符合率均无显著差异(P>0.05)。结论 fFN和IGFBP-1是预测早产的有效指标，联合应用可最大限度提高诊断符合率。
목적：평개태인섬유련접단백(fFN)화이도소양생장인자결합단백-1(IGFBP-1)재조산예측중적림상개치。방법선택선조조산잉부210례，수궤분위삼조각70례，응용면역법정성검측궁경음도분비물중적fFN화IGFBP-1。A조행fFN검측，B조행IGFBP-1검측，C조행이자연합검측，관찰7d、14d내분면결국，계산삼충방법예측조산적령민도、특이성、양성예측치、음성예측치화진단부합솔。결과 A조중19례양성,51례음성。B조중21례양성，49례음성。C조량자지일양성혹량자균양성혹공33례，량자균음성37례。삼충검측방법재7d화14d내예측적령민도、특이도、양성예측치、음성예측치화진단부합솔균무현저차이(P>0.05)。결론 fFN화IGFBP-1시예측조산적유효지표，연합응용가최대한도제고진단부합솔。
Objective To evaluate the clinical value of the fetal fibronection(fFN) and insulin-like growth factor binding protein-1(IGFBP-1) in prediction of premature delivery. Methods 210 cases of pregnant women with threatened abortion were randomly divided into three groups, each group have 70 cases. Qualitative detected fFN and IGFBP-1 in the cervical vaginal secretions by immunoassays. Group A only detected fFN and group B only detected IGFBP-1, group C detected fFN and IGFBP-1, observation delivery outcome within 1 week, 2 weeks.Then calculate the sensitivity, specificity, positive predictive value, negative predictive value and the diagnosis coincidence rate of each group. Results Group A have 19 positive cases and 51 negative cases. Group B have 21 positive cases and 49 negative cases. Group C have 33 positive cases either or both of fFN and IGFBP-1, and both of fFN and IGFBP-1 were negative 37 cases. Statistical analysis the prognostic sensitivity, specificity, positive predictive value, negative predictive value and the diagnosis coincidence rate within 7 days or 14 days among three groups, and there were no significant difference(P>0.05). Conclusion fFN and IGFBP-1 are effective predictors to predict premature delivery; The combined application of fFN and IGFBP-1 can improve the diagnosis coincidence rate.